Switch theme
Sign up to access all valuation multiples
Jiangsu Nhwa Pharmaceutical Co Ltd is a drug manufacturer. The company is engaged in manufacturing of APIs and dosages.
2007
1.6K+
LTM Revenue $837M
LTM EBITDA $207M
$2.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Jiangsu Nhwa has a last 12-month revenue (LTM) of $837M and a last 12-month EBITDA of $207M.
In the most recent fiscal year, Jiangsu Nhwa achieved revenue of $791M and an EBITDA of $206M.
Jiangsu Nhwa expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Jiangsu Nhwa valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $837M | XXX | $791M | XXX | XXX | XXX |
| Gross Profit | $620M | XXX | $582M | XXX | XXX | XXX |
| Gross Margin | 74% | XXX | 74% | XXX | XXX | XXX |
| EBITDA | $207M | XXX | $206M | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 26% | XXX | XXX | XXX |
| EBIT | $194M | XXX | $184M | XXX | XXX | XXX |
| EBIT Margin | 23% | XXX | 23% | XXX | XXX | XXX |
| Net Profit | $168M | XXX | $159M | XXX | XXX | XXX |
| Net Margin | 20% | XXX | 20% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Jiangsu Nhwa's stock price is CNY 23 (or $3).
Jiangsu Nhwa has current market cap of CNY 23.5B (or $3.3B), and EV of CNY 19.5B (or $2.7B).
See Jiangsu Nhwa trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.7B | $3.3B | XXX | XXX | XXX | XXX | $0.17 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Jiangsu Nhwa has market cap of $3.3B and EV of $2.7B.
Jiangsu Nhwa's trades at 3.4x EV/Revenue multiple, and 13.2x EV/EBITDA.
Equity research analysts estimate Jiangsu Nhwa's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Jiangsu Nhwa has a P/E ratio of 19.4x.
See valuation multiples for Jiangsu Nhwa and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3.3B | XXX | $3.3B | XXX | XXX | XXX |
| EV (current) | $2.7B | XXX | $2.7B | XXX | XXX | XXX |
| EV/Revenue | 3.2x | XXX | 3.4x | XXX | XXX | XXX |
| EV/EBITDA | 13.1x | XXX | 13.2x | XXX | XXX | XXX |
| EV/EBIT | 14.0x | XXX | 14.7x | XXX | XXX | XXX |
| EV/Gross Profit | 4.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | 19.4x | XXX | 20.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 41.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialJiangsu Nhwa's last 12 month revenue growth is 14%
Jiangsu Nhwa's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.2M for the same period.
Jiangsu Nhwa's rule of 40 is 40% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Jiangsu Nhwa's rule of X is 59% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Jiangsu Nhwa and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 14% | XXX | 14% | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 26% | XXX | XXX | XXX |
| EBITDA Growth | 15% | XXX | 9% | XXX | XXX | XXX |
| Rule of 40 | 40% | XXX | 40% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 59% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 28% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 10% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 50% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Jiangsu Nhwa acquired XXX companies to date.
Last acquisition by Jiangsu Nhwa was XXXXXXXX, XXXXX XXXXX XXXXXX . Jiangsu Nhwa acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Jiangsu Nhwa founded? | Jiangsu Nhwa was founded in 2007. |
| Where is Jiangsu Nhwa headquartered? | Jiangsu Nhwa is headquartered in China. |
| How many employees does Jiangsu Nhwa have? | As of today, Jiangsu Nhwa has 1.6K+ employees. |
| Is Jiangsu Nhwa publicy listed? | Yes, Jiangsu Nhwa is a public company listed on SHE. |
| What is the stock symbol of Jiangsu Nhwa? | Jiangsu Nhwa trades under 002262 ticker. |
| When did Jiangsu Nhwa go public? | Jiangsu Nhwa went public in 2008. |
| Who are competitors of Jiangsu Nhwa? | Similar companies to Jiangsu Nhwa include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Jiangsu Nhwa? | Jiangsu Nhwa's current market cap is $3.3B |
| What is the current revenue of Jiangsu Nhwa? | Jiangsu Nhwa's last 12 months revenue is $837M. |
| What is the current revenue growth of Jiangsu Nhwa? | Jiangsu Nhwa revenue growth (NTM/LTM) is 14%. |
| What is the current EV/Revenue multiple of Jiangsu Nhwa? | Current revenue multiple of Jiangsu Nhwa is 3.2x. |
| Is Jiangsu Nhwa profitable? | Yes, Jiangsu Nhwa is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Jiangsu Nhwa? | Jiangsu Nhwa's last 12 months EBITDA is $207M. |
| What is Jiangsu Nhwa's EBITDA margin? | Jiangsu Nhwa's last 12 months EBITDA margin is 25%. |
| What is the current EV/EBITDA multiple of Jiangsu Nhwa? | Current EBITDA multiple of Jiangsu Nhwa is 13.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
